Wanbury shines on getting EIR from USFDA for Maharashtra manufacturing facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Wanbury is currently trading at Rs. 218.20, up by 8.20 points or 3.90% from its previous closing of Rs. 210.00 on the BSE.
The scrip opened at Rs. 213.60 and has touched a high and low of Rs. 220.50 and Rs. 213.00 respectively. So far 66631 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 223.00 on 29-Jul-2024 and a 52 week low of Rs. 51.40 on 28-Aug-2023.
Last one week high and low of the scrip stood at Rs. 220.50 and Rs. 188.00 respectively. The current market cap of the company is Rs. 704.03 crore.
The promoters holding in the company stood at 39.79%, while Institutions and Non-Institutions held 0.22% and 59.98% respectively.
Wanbury has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its manufacturing facility located at MIDC Industrial Area, Patalganga, Maharashtra, India and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is ‘No Action Indicated’ (NAI) with zero 483 observation.
Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation.
